Adjunctive rufinamide in Lennox-Gastaut syndrome: A long-term, open-label extension study

G. Kluger, T. Glauser, G. Krauss, R. Seeruthun, C. Perdomo, S. Arroyo

Research output: Contribution to journalArticlepeer-review

74 Scopus citations


Objective - This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study. Materials and methods - In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide ∼25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests. Results - Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had ≥50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%). Conclusions - In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.

Original languageEnglish (US)
Pages (from-to)202-208
Number of pages7
JournalActa Neurologica Scandinavica
Issue number3
StatePublished - Sep 2010


  • Lennox-Gastaut syndrome
  • epilepsy
  • extension study
  • open-label
  • rufinamide
  • tonic-atonic seizures
  • total seizures

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Adjunctive rufinamide in Lennox-Gastaut syndrome: A long-term, open-label extension study'. Together they form a unique fingerprint.

Cite this